Antigen Shedding May Improve Efficiencies for Delivery of Antibody-Based Anticancer Agents in Solid Tumors

被引：33

作者：

Pak, Youngshang ^{[2
,3
]}

Zhang, Yujian ^{[1
]}

Pastan, Ira ^{[1
]}

Lee, Byungkook ^{[1
]}

机构：

[1] NCI, Lab Mol Biol, NIH, Bethesda, MD 20892 USA

[2] Pusan Natl Univ, Dept Chem, Pusan, South Korea

[3] Pusan Natl Univ, Inst Funct Mat, Pusan, South Korea

来源：

CANCER RESEARCH | 2012年 / 72卷 / 13期

关键词：

BINDING-SITE BARRIER; RECOMBINANT IMMUNOTOXIN; MONOCLONAL-ANTIBODIES; PSEUDOMONAS EXOTOXIN; ANTITUMOR-ACTIVITY; DRUG-DELIVERY; PHASE-I; CANCER; SS1P; THERAPY;

D O I：

10.1158/0008-5472.CAN-11-3925

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recombinant immunotoxins (RIT) are targeted anticancer agents that are composed of a targeting antibody fragment and a protein toxin fragment. SS1P is a RIT that targets mesothelin on the surface of cancer cells and is being evaluated in patients with mesothelioma. Mesothelin, like many other target antigens, is shed from the cell surface. However, whether antigen shedding positively or negatively affects the delivery of RIT remains unknown. In this study, we used experimental data with SS1P to develop a mathematical model that describes the relationship between tumor volume changes and the dose level of the administered RIT, while accounting for the potential effects of antigen shedding. Cancer Res; 72(13); 3143-52. (C) 2012 AACR.

引用

页码：3143 / 3152

页数：10

共 35 条

[1] Monoclonal antibody therapy of cancer
Adams, GP
Weiner, LM
[J]. NATURE BIOTECHNOLOGY, 2005, 23 (09) : 1147 - 1157
[2] Inhibition of Tumor Growth by Targeted Toxins in Mice is Dramatically Improved by Saponinum Album in a Synergistic Way
Bachran, Christopher
Duerkop, Horst
Sutherland, Mark
Bachran, Diana
Mueller, Christian
Weng, Alexander
Melzig, Matthias F.
Fuchs, Hendrik
[J]. JOURNAL OF IMMUNOTHERAPY, 2009, 32 (07) : 713 - 725
[3] Belting Mattias, 2009, V480, P1, DOI 10.1007/978-1-59745-429-2_1
[4] Modeling recombinant immunotoxin efficacies in solid tumors
Chen, Kevin C.
Kim, Junho
Li, Xinmei
Lee, Byungkook
[J]. ANNALS OF BIOMEDICAL ENGINEERING, 2008, 36 (03) : 486 - 512
[5] FUJIMORI K, 1990, J NUCL MED, V31, P1191
[6] Graff CP, 2003, CANCER RES, V63, P1288
[7] Mesothelin targeted cancer immunotherapy
Hassan, Raffit
Ho, Mitchell
[J]. EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 46 - 53
[8] Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
Hassan, Raffit
Bullock, Susie
Premkumar, Ahalya
Kreitman, Robert J.
Kindler, Hedy
Willingham, Mark C.
Pastan, Ira
[J]. CLINICAL CANCER RESEARCH, 2007, 13 (17) : 5144 - 5149
[9] Vascular tumor growth and treatment: Consequences of polyclonality, competition and dynamic vascular support
Jackson, TL
[J]. JOURNAL OF MATHEMATICAL BIOLOGY, 2002, 44 (03) : 201 - 226
[10] A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy
Jackson, TL
Byrne, HM
[J]. MATHEMATICAL BIOSCIENCES, 2000, 164 (01) : 17 - 38

← 1 2 3 4 →